Swedish biotechnology company Anocca has secured approximately Skr440m ($46m) to primarily support the early-stage clinical trials of non-viral gene-edited TCR-T cell therapy, VIDAR-1, aimed at mutant KRAS in pancreatic cancer.
Additionally, the investment will facilitate the progression of the company’s preclinical pipeline.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The financing round was spearheaded by the family-owned investment entity Mellby Gård, with contributions from Ramsbury, AMF and current shareholders.
New investors also participated in the funding round.
Anocca has announced the commencement of recruitment for Phase I of the cell therapy trial.
This multi-centre study is being carried out across several university hospitals located in Denmark, Germany, the Netherlands and Sweden.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe VIDAR-1 trial is structured as an umbrella study encompassing various products that target oncogenic driver KRAS mutations within pancreatic ductal adenocarcinoma (PDAC).
It aims to include up to 20 subjects per product across a series of Phase I/II trials.
Currently, Phase I is active at eight locations across four nations, with plans to expand to additional sites and nations in Phase II.
Eligibility for enrolment is contingent upon subjects having a specific HLA and KRAS mutation that corresponds with an available product.
SEB Corporate Finance provided financial advisory services to Anocca during the transaction’s completion.
Legal counsel was provided by Mannheimer Swartling and HWF Advokater.
Anocca CEO and co-founder Reagan Jarvis said: “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic.
“The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.”
In March 2025, Anocca received authorisation from regulatory authorities in four European nations to proceed with its Phase I/II VIDAR-1trial.
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
